Subtopic Deep Dive
Relaxin Therapeutic Applications
Research Guide
What is Relaxin Therapeutic Applications?
Relaxin therapeutic applications investigate recombinant relaxin (serelaxin) for treating acute heart failure, pulmonary hypertension, and fibrosis through antifibrotic and hemodynamic effects mediated by RXFP1 receptors.
Serelaxin infusions were tested in phase III trials like RELAX-AHF for acute heart failure patients, showing no reduction in 180-day cardiovascular death but potential short-term benefits (Metra et al., 2019, 253 citations). Relaxin inhibits TGF-β/Smad3 signaling via Notch-1 to prevent cardiac fibroblast-myofibroblast transition (Sassoli et al., 2013, 131 citations). Over 1,200 citations across 12 key papers document its RXFP1-mediated cardioprotective mechanisms (Du et al., 2009, 185 citations).
Why It Matters
Serelaxin addresses unmet needs in acute heart failure by improving renal function and hemodynamics, as shown in RELAX-AHF where it reduced worsening heart failure at day 5 (Metra et al., 2019). Anti-fibrotic effects mitigate liver metastasis and synergize with checkpoint therapy via hepatic stellate cell inhibition (Hu et al., 2019). Samuel et al. (2016) detail relaxin's role in reducing organ scarring, contributing to 45-50% of fibrosis-related deaths. Clinical translation from RXFP1 signaling advances therapies for cardiovascular fibrosis (Halls et al., 2015).
Key Research Challenges
Clinical Efficacy Failure
Serelaxin failed to lower 180-day cardiovascular death or worsening heart failure in RELAX-AHF phase III trial despite preclinical promise (Metra et al., 2019). Teichman et al. (2010) note inconsistent translation from animal models to humans. Troponin T elevations persist, complicating prognosis (Felker et al., 2015).
Fibrosis Mechanism Variability
Relaxin inhibits TGF-β/Smad3 via Notch-1 in cardiac fibroblasts, but effects vary across organs like liver and heart (Sassoli et al., 2013; Hu et al., 2019). Samuel et al. (2016) highlight inconsistent antifibrotic responses in different injury models. Lü et al. (2017) report challenges in targeting cardiac fibrosis specifically.
RXFP1 Receptor Translation
RXFP1-mediated effects show promise in basic science but limited clinical success (Du et al., 2009; Halls et al., 2015). Fisher et al. (2003) found relaxin levels do not predict chronic heart failure outcomes unlike NT-proBNP. Dose optimization remains unresolved in serelaxin trials.
Essential Papers
Rare diseases bullet 8: Organising pneumonia
J.F. Cordier · 2000 · Thorax · 301 citations
Effects of Serelaxin in Patients with Acute Heart Failure
Marco Metra, John R. Teerlink, Gad Cotter et al. · 2019 · New England Journal of Medicine · 253 citations
In this trial involving patients who were hospitalized for acute heart failure, an infusion of serelaxin did not result in a lower incidence of death from cardiovascular causes at 180 days or worse...
Cardiovascular effects of relaxin: from basic science to clinical therapy
Xiao‐Jun Du, Ross A. D. Bathgate, Chrishan S. Samuel et al. · 2009 · Nature Reviews Cardiology · 185 citations
A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease
Fang Lü, Andrew Murphy, Anthony M. Dart · 2017 · Frontiers in Pharmacology · 149 citations
Cardiac fibrosis are central to various cardiovascular diseases. Research on the mechanisms and therapeutic targets for cardiac fibrosis has advanced greatly in recent years. However, while many an...
Relaxin: Review of Biology and Potential Role in Treating Heart Failure
Sam L. Teichman, Elaine Unemori, John R. Teerlink et al. · 2010 · Current Heart Failure Reports · 142 citations
International Union of Basic and Clinical Pharmacology. XCV. Recent Advances in the Understanding of the Pharmacology and Biological Roles of Relaxin Family Peptide Receptors 1–4, the Receptors for Relaxin Family Peptides
Michelle L. Halls, Ross A. D. Bathgate, Steve W. Sutton et al. · 2015 · Pharmacological Reviews · 133 citations
Serial High Sensitivity Cardiac Troponin T Measurement in Acute Heart Failure: Insights from the Relax-Ahf Study
G. Michael Felker, Robert J. Mentz, John R. Teerlink et al. · 2015 · European Journal of Heart Failure · 131 citations
Abstract Aims Troponin elevation is common in acute heart failure (AHF) and may be useful for prognostication; however, available data are mixed and many previous studies used older, less sensitive...
Reading Guide
Foundational Papers
Start with Du et al. (2009, 185 citations) for RXFP1 cardiovascular mechanisms, then Teichman et al. (2010, 142 citations) for heart failure biology review, and Sassoli et al. (2013, 131 citations) for Notch-1 antifibrotic pathway details.
Recent Advances
Study Metra et al. (2019, 253 citations) RELAX-AHF trial failure, Hu et al. (2019) liver metastasis synergy, and Samuel et al. (2016, 126 citations) organ fibrosis actions.
Core Methods
Core techniques include serelaxin infusions in AHF trials (Metra et al., 2019), serial hs-cTnT measurements (Felker et al., 2015), Notch-1 inhibition of TGF-β/Smad3 (Sassoli et al., 2013), and RXFP1 pharmacology (Halls et al., 2015).
How PapersFlow Helps You Research Relaxin Therapeutic Applications
Discover & Search
Research Agent uses searchPapers and citationGraph to map 253-cited RELAX-AHF trial (Metra et al., 2019) connections to 185-cited review by Du et al. (2009), revealing RXFP1 pathways. exaSearch uncovers fibrosis applications like Hu et al. (2019); findSimilarPapers expands to Samuel et al. (2016) anti-fibrotic mechanisms.
Analyze & Verify
Analysis Agent employs readPaperContent on Metra et al. (2019) to extract day-5 vs. 180-day endpoints, then verifyResponse with CoVe checks claims against Felker et al. (2015) troponin data. runPythonAnalysis performs GRADE grading on trial outcomes and statistical verification of hazard ratios using pandas for RELAX-AHF survival curves.
Synthesize & Write
Synthesis Agent detects gaps in serelaxin efficacy post-RELAX-AHF via contradiction flagging between preclinical (Sassoli et al., 2013) and clinical data. Writing Agent uses latexEditText, latexSyncCitations for 12-paper review, latexCompile for publication-ready manuscript, and exportMermaid for RXFP1-TGF-β pathway diagrams.
Use Cases
"Extract survival data from RELAX-AHF and plot hazard ratios for serelaxin vs placebo."
Research Agent → searchPapers('RELAX-AHF') → Analysis Agent → readPaperContent(Metra 2019) → runPythonAnalysis(pandas/matplotlib hazard ratio plot, GRADE B evidence) → researcher gets CSV export with verified curves.
"Draft LaTeX review of relaxin antifibrotic trials with citations."
Research Agent → citationGraph(Du 2009, Samuel 2016) → Synthesis Agent → gap detection → Writing Agent → latexEditText(structured sections) → latexSyncCitations(12 papers) → latexCompile(PDF) → researcher gets compiled review with synced refs.
"Find GitHub repos analyzing RELAX-AHF troponin data."
Research Agent → searchPapers('RELAX-AHF troponin') → Code Discovery → paperExtractUrls(Felker 2015) → paperFindGithubRepo → githubRepoInspect → researcher gets repo code, notebooks for serial hs-cTnT analysis.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ relaxin papers, chaining searchPapers → citationGraph → DeepScan for 7-step RELAX-AHF analysis with GRADE checkpoints on Metra et al. (2019). Theorizer generates hypotheses on RXFP1 failure modes from Du et al. (2009) and Halls et al. (2015), verified via CoVe. DeepScan verifies antifibrotic synergies in Hu et al. (2019) with runPythonAnalysis on metastasis data.
Frequently Asked Questions
What is the definition of relaxin therapeutic applications?
Relaxin therapeutic applications focus on recombinant serelaxin for acute heart failure, fibrosis, and pulmonary hypertension via RXFP1-mediated antifibrotic and hemodynamic effects (Du et al., 2009).
What methods are used in relaxin trials?
Phase III trials like RELAX-AHF use 48-hour serelaxin infusions, assessing cardiovascular death, heart failure worsening, and biomarkers like troponin T via serial measurements (Metra et al., 2019; Felker et al., 2015).
What are key papers on relaxin?
Top papers include Metra et al. (2019, 253 citations, RELAX-AHF trial), Du et al. (2009, 185 citations, cardiovascular effects), and Samuel et al. (2016, 126 citations, anti-fibrotic actions).
What open problems exist?
Challenges include serelaxin failing 180-day endpoints despite preclinical antifibrotic success via Notch-1/TGF-β (Metra et al., 2019; Sassoli et al., 2013), and poor prognostic prediction in chronic heart failure (Fisher et al., 2003).
Research Pregnancy-related medical research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Relaxin Therapeutic Applications with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers